Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brown, Linda
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Jan 2024 - Dec 2024: Market entry for acute leukemias Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Data from P1 portion of AUGMENT-101 trial for Leukemia Nov 2022 - Nov 2022: Data from P1 portion of AUGMENT-101 trial for Leukemia Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 Nov 2021 - Nov 2021: Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Apr 2021 - Apr 2021: From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Data from AUGMENT-101 trial for AML Dec 2021 - Dec 2020: Data from AUGMENT-101 trial for AML More	Recruiting	1/2	413	Europe, Canada, US, RoW	revumenib, SNDX-5613, cobicistat	Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage	12/27	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brown, Linda
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Jan 2024 - Dec 2024: Market entry for acute leukemias Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Data from P1 portion of AUGMENT-101 trial for Leukemia Nov 2022 - Nov 2022: Data from P1 portion of AUGMENT-101 trial for Leukemia Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 Nov 2021 - Nov 2021: Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Apr 2021 - Apr 2021: From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Data from AUGMENT-101 trial for AML Dec 2021 - Dec 2020: Data from AUGMENT-101 trial for AML More	Recruiting	1/2	413	Europe, Canada, US, RoW	revumenib, SNDX-5613, cobicistat	Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage	12/27	12/27